Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prokidney (PROK) Research & Development (2022 - 2025)

Prokidney (PROK) has disclosed Research & Development for 4 consecutive years, with $34.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 14.14% to $34.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.1 million through Dec 2025, down 10.61% year-over-year, with the annual reading at $114.1 million for FY2025, 10.61% down from the prior year.
  • Research & Development for Q4 2025 was $34.2 million at Prokidney, up from $26.8 million in the prior quarter.
  • The five-year high for Research & Development was $39.8 million in Q4 2024, with the low at $11.6 million in Q2 2022.
  • Average Research & Development over 4 years is $26.9 million, with a median of $27.0 million recorded in 2024.
  • The sharpest move saw Research & Development skyrocketed 128.1% in 2023, then dropped 14.17% in 2025.
  • Over 4 years, Research & Development stood at $20.9 million in 2022, then increased by 7.84% to $22.5 million in 2023, then skyrocketed by 76.58% to $39.8 million in 2024, then fell by 14.14% to $34.2 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $34.2 million, $26.8 million, and $25.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.